Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: Am J Transplant. 2023 Apr 4;23(8):1171–1181. doi: 10.1016/j.ajt.2023.03.022

Figure 4.

Figure 4.

Histopathologic findings. (A) Renal allograft at autopsy on day 28 from a recipient (M3920) in the stTNX/mono group showed T cell–mediated rejection (TCMR) type 3. (B) The remaining 4 recipients did well without rejection. The picture is a representative biopsy from M10521 on day 174, showing no diagnostic abnormality and no C4d staining (C). (D) Biopsy from M5321 (loTNX/MMF) on day 47 showed TCMR type 3 and positive C4d deposition (E). (F) Representative biopsy taken on day 184 from a recipient in the loTNX/MMF group, showed no rejection. loTNX/MMF, low-dose TNX + mycophenolate mofetil; stTNX/mono, standard-dose TNX monotherapy.